Skip to Main Content

Paper Details

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Cancer Discov
87
2016
AKT, EGFR, ERK, EZH2, EZH2-dependent cancers, EZH2-driven tumors, JQEZ5, KRAS, KRAS- and EGFR-mutant mouse lung cancers, Lung Cancer, NSCLC, chromatin, developmental gene networks, epithelial cancers, human, lung adenocarcinoma, lung adenocarcinomas, lung cancer, lung cancers, lysine, lysine methyltransferase, mouse, murine, non-small cell lung carcinoma, tumors
Author NameAffiliation
Jun QiDana-Farber Cancer Institute, Harvard Medical School
Lewyn LiCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Alexander J FederationDana-Farber Cancer Institute, Harvard Medical School
Thomas De RaedtHarvard Medical School, Brigham and Women's Hospital
Charles M PerouThe University of North Carolina at Chapel Hill
Peter S HammermanDana-Farber Cancer Institute, Harvard Medical School
Peter S HammermanDana-Farber Cancer Institute, Harvard Medical School
Myles BrownHarvard Medical School, Massachusetts. Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
James E BradnerDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 9

Datasets

Release 1.2